Clinical data demonstrates DynamX Bioadaptor restores vessel motion and function

Clinical data demonstrates DynamX Bioadaptor restores vessel motion and function

Dubai, UAE: – Elixir Medical, a developer of breakthrough cardiovascular technologies with a strong presence in the Middle East market, today announced that the large international randomized BIOADAPTOR RCT trial of the company’s DynamX® Coronary Drug-Eluting Bioadaptor compared to Resolute OnyxTM Drug-Eluting Stent met its primary endpoint of Target Lesion Failure (TLF) non-inferiority at 12 months. DynamX Bioadaptor is a new type of coronary implant designed to unlock the scaffold, uncage the vessel, to return normal vessel motion and function after percutaneous coronary intervention (PCI), with continued dynamic support of the atherosclerotic vessel to reduce long-term adverse events.

Cardiovascular diseases (CDA) are on the rise in the region and are responsible for 34% of all deaths in the Middle East population[1]. DynamX is designed to improve the treatment of one of the most prevalent cardiovascular conditions, coronary artery disease.

As per the findings of the study, presented during the EuroPCR 2023 conference in Paris, the novel bioadaptor scaffold achieved a very low 1.8% TLF rate compared to 2.8% for Resolute Onyx DES (p<0.001), as well as similar acute performance, acute lumen gain, and percent diameter stenosis at baseline. And, for the first time seen in a coronary revascularization implant, the bioadaptor scaffold